Ferdinando Nicoletti

ORCID: 0000-0003-3366-7269
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroscience and Neuropharmacology Research
  • Anesthesia and Neurotoxicity Research
  • Neurological Disorders and Treatments
  • Pain Mechanisms and Treatments
  • Receptor Mechanisms and Signaling
  • Autism Spectrum Disorder Research
  • Parkinson's Disease Mechanisms and Treatments
  • Zebrafish Biomedical Research Applications
  • Congenital heart defects research
  • Genetics and Neurodevelopmental Disorders
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Neuropeptides and Animal Physiology
  • Birth, Development, and Health
  • Intracranial Aneurysms: Treatment and Complications
  • Mental Health and Psychiatry
  • Pain Management and Opioid Use
  • Health Systems, Economic Evaluations, Quality of Life
  • Signaling Pathways in Disease
  • Pluripotent Stem Cells Research
  • Genomic variations and chromosomal abnormalities
  • Culinary Culture and Tourism
  • Amino Acid Enzymes and Metabolism
  • Conducting polymers and applications
  • Lysosomal Storage Disorders Research
  • Pharmacological Effects and Toxicity Studies

Istituto Neurologico Mediterraneo
1983-2025

Sapienza University of Rome
2007-2025

Azienda Ospedaliera Pugliese Ciaccio
2010

Université Lille Nord de France
2009

University of Catania
1987-2007

University of Siena
2003

Georgetown University
1986

Abstract We moved from the hypothesis that perineuronal nets (PNNs), which are condensed structures of extracellular matrix surrounding GABAergic interneurons in forebrain, contribute to mechanisms maladaptive neuronal plasticity underlying chronic pain. Here, we found density PNNs labelled with lectin Wisteria Floribunda Agglutinin (WFA) increased contralateral somatosensory cortex (SSC), medial prefrontal (mPFC), reticular thalamic nucleus (RTN), and insular mice developing neuropathic...

10.1097/j.pain.0000000000003563 article EN cc-by-nc-nd Pain 2025-03-17

Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson's disease (PD). Here we focused on mGlu3, a receptor subtype involved synaptic regulation and neuroinflammation. mGlu3−/− mice showed an enhanced nigro-striatal damage microglial activation response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Expression of genes encoding anti-inflammatory proteins neuroprotective factors was reduced the striatum MPTP-treated mice. We also...

10.1038/s41531-024-00860-6 article EN cc-by-nc-nd npj Parkinson s Disease 2025-01-04

Aripiprazole as a long-acting injectable (LAI) is initiated in oral aripiprazole-stabilised patients and needs, after first injection, 14 days supplementation of aripiprazole (one-injection start, OIS). Recently, an alternative two-injection start (TIS) was advanced, involving two 400 mg injections with single 20 aripiprazole. We tested the regimens schizophrenia (SCZ, n = 152, 90 men 62 women) (SUD+; 93) or without (SUD–; 59) substance use disorders (SUDs), comparing OIS (n 66) TIS 86) SUD+...

10.3390/ijms26031394 article EN International Journal of Molecular Sciences 2025-02-06

Introduction/Objective: Esketamine is administered intranasally in combination with at least another antidepressant patients treatment-resistant depression. Some of these antidepressants might affect ketamine’s pharmacokinetic profile by inhibiting cytochrome-P450 (CYP450) isoforms. Our aim was to establish how different types combined serum and salivary levels esketamine the time maximum plasma concentrations afterward TRD receiving a real-world context. Methods: Serum samples were...

10.2174/011570159x356952241216172603 article EN Current Neuropharmacology 2025-04-07

The concept of inflammation-induced sensitization is emerging in the field perinatal brain injury, stroke, Alzheimer disease, and multiple sclerosis. However, mechanisms underpinning this process remain unidentified.We combined vivo systemic lipopolysaccharide-induced or interleukin (IL)-1β-induced neonatal adult rodent cortical neurons to excitotoxic neurodegeneration with vitro IL-1β human neurodegeneration. Within these models, we assessed metabotropic glutamate receptors (mGluR)...

10.1002/ana.23868 article EN Annals of Neurology 2013-02-11

Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental condition with several identified risk factors, both genetic and non-genetic. Among these, prenatal exposure to valproic acid (VPA) has been extensively associated the development of disorder. The zebrafish, cost- time-effective model, useful for studying ASD features. Using validated VPA-induced zebrafish models, we aimed provide new insights into VPA effects during embryonic identify potential biomarkers ASD-like...

10.3390/cells13161349 article EN cc-by Cells 2024-08-14

Abstract Background and Hypothesis Type-1 trace amine-associated receptors (TAAR1) modulate dopaminergic glutamatergic neurotransmission are targeted by novel antipsychotic drugs. We hypothesized that schizophrenia (SCZ) causes adaptive changes in TAAR1 expression the prefrontal cortex. Study Design measured mRNA protein levels quantitative PCR immunoblotting post-mortem cortical samples obtained from 23 individuals affected SCZ non-schizophrenic controls (CTRL). Data were correlated with a...

10.1093/schbul/sbad148 article EN Schizophrenia Bulletin 2023-10-28

A new series of compounds were designed as structural analogues the alpha(1)-AR ligand RN5 (4), characterized by a tricyclic 5H-pyrimido[5,4-b]indole-(1H,3H)2,4-dione system connected through an alkyl chain to phenylpiperazine (PP) moiety. These synthesized and tested in binding assays on human alpha(1A)-AR, alpha(1B)-AR, alpha(1D)-AR subtypes expressed HEK293 cells. Several modifications performed PP moiety, system, connecting chain. Many molecules showed preferential affinity for subtype....

10.1021/jm0307741 article EN Journal of Medicinal Chemistry 2003-06-07

Background: Although it is generally believed that chronic ethanol consumption impairs learning and memory, results obtained in experimental animals are not univocal, there conditions which paradoxically improves cognitive functions. In the present work, we investigated effects of prenatal stress exposure during adulthood on spatial memory rats. Methods: Rats were subjected to a delivered as 3 daily 45‐minute sections restraint mothers last 10 days pregnancy (PRS rats). After 7 months...

10.1111/j.1530-0277.2009.00964.x article EN Alcoholism Clinical and Experimental Research 2009-04-30

SOX-3 is a transcription factor expressed throughout the developing central nervous system and involved in maintenance of pluripotency self-renewing stem cells, specification events, lineage progression, terminal differentiation. An association between growth hormone deficiency, mental retardation, Sox-3 mutations humans was previously reported. The occurrence abnormalities affecting polyalanine tract gene determined group 77 unrelated mentally retarded patients without definite genetic...

10.1089/gte.2006.0510 article EN Genetic Testing 2007-06-01

Fabry disease (FD) is a X-linked lysosomal storage disorder caused by deficient function of the alpha-galactosidase A (α-GalA) enzyme. α-GalA deficiency leads to multisystemic clinical manifestations preferential accumulation globotriaosylceramide (Gb3). hallmark symptom FD patients neuropathic pain that appears in early stage as result peripheral small fiber damage. Previous studies have shown Acetyl-L-carnitine (ALC) has neuroprotective, neurotrophic, and analgesic activity animal models...

10.1177/17448069221087033 article EN cc-by-nc Molecular Pain 2022-03-08

Background: Citicoline and homotaurine are compounds with a potent neuroprotective activity they have been administered for many years in the treatment of numerous neurodegenerative ophthalmological diseases, including glaucoma. Initially available only as liquid form, through parenteral route, nowadays citicoline can be also tablet but no data on bioavailability these different forms available. In present study, pharmacokinetics versus vials, each at therapeutic dose 500 mg, addition to 50...

10.4236/jbise.2019.127028 article EN Journal of Biomedical Science and Engineering 2019-01-01

SYNOPSIS We investigated the therapeutic efficacy of short‐term (Asu 1,7 )eel‐calcitonin treatment in subjects affected by headache. All 47 patients were initially treated for 20 days intramuscularly with vehicle alone (basal values). Subsequently, they received another 10 a daily injection )eel calcitonin (40 I.U. per day i.m.). The effectiveness was evaluated terms changes frequency, intensity and duration migraine attacks, pain chronic levels plasma calcitonin, before, during at end...

10.1111/j.1526-4610.1987.hed2706334.x article EN Headache The Journal of Head and Face Pain 1987-06-01
Coming Soon ...